Piper Sandler analyst Biren Amin assumed coverage of Kalaris Therapeutics (KLRS) with a Neutral rating and $3 price target The firm says the preclinical data for the company’s anti-VEGF, TH103, do not offer differentiation when compared to the standard of care in retinal diseases. Piper is on the sidelines pending better clarity on TH103’s clinical profile.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: